ERYTECH Pharma S.A.
$0.80▲ 0.25%(+$0.00)
TickerSpark Score
71/100
▌ Solid
87
Valuation
80
Profitability
60
Growth
68
Health
60
Momentum
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERYP.PA research report →
52-Week Range43% of range
Low
$0.28
Current
$0.80
High
$1.48
Company Overviewwww.erytech.com
About the company
ERYTECH Pharma S. A. is a clinical-stage biopharmaceutical company focused on creating innovative therapies derived from red blood cells.
- CEO
- Gil Beyen
- IPO
- 2013
- Employees
- 49
- HQ
- Lyon, FR
Price Chart
-29.37% · this period
Valuation
- Market Cap
- $48.66M
- P/E
- -0.02
- P/S
- 0.76
- P/B
- 0.02
- EV/EBITDA
- -0.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1784.31%
- Net Margin
- -1771.34%
- ROE
- -95.68%
- ROIC
- -56.27%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-228,000 · 99.58%
- EPS
- $-0.01 · 99.67%
- Op Income
- $-2,796,000
- FCF YoY
- 44.19%
Performance & Tape
- 52W High
- $1.48
- 52W Low
- $0.28
- 50D MA
- $0.87
- 200D MA
- $0.75
- Beta
- 2.13
- Avg Volume
- 215.20K
Get TickerSpark's AI analysis on ERYP.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Coverage · ERYP.PA
Our ERYP.PA coverage
Recent articles, reports, and earnings notes.
On-Demand Research
No research on ERYP.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ERYP.PA report →Internal Compare
Similar companies
Peers in the same neighborhood.